Nivolumab vs Trastuzumab
Nivolumab vs Trastuzumab: Overview
This comparison examines the pharmacological differences between Nivolumab and Trastuzumab.
Mechanism of Action
Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.
Trastuzumab: Anti-HER2 monoclonal antibody inhibiting receptor signaling.
Pharmacokinetics
Half-life: Nivolumab — 27 days; Trastuzumab — 28 days.
Chemical Properties
Type: Nivolumab — Antibody; Trastuzumab — Antibody.